Bharat Parenterals Ltd — Board Meeting, 28-07-2025: Board Meeting

Bharat Parenterals' board has approved the financial results for the quarter ended June 30, 2025, and provided a business update. Standalone revenue hit ₹94.37 Cr with ₹10 Cr net profit. Consolidated revenue reached ₹116 Cr, with net loss significantly narrowing to ₹0.87 Cr, indicating strong performance. The company also announced its 32nd Annual General Meeting for September 26, 2025. Key leadership changes include a director's resignation and new appointments for directors and statutory auditors, subject to shareholder approval. Operational highlights include Innoxel's growing pipeline and Varenyam Healthcare's strong hospital presence. The company projects 12-14% standalone revenue growth for FY26.